Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Entrada Therapeutics Q2 2024 GAAP EPS $1.55 May Not Be Comparable To $0.10 Estimate, Sales $94.694M May Not Be Comparable To $46.075M Estimate

Author: Benzinga Newsdesk | August 13, 2024 07:18am

Posted In: TRDA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist